Welcome to our dedicated page for Vivani Medical news (Ticker: VANI), a resource for investors and traders seeking the latest updates and insights on Vivani Medical stock.
Vivani Medical, Inc. reports developments from a clinical-stage biopharmaceutical business focused on miniature, ultra long-acting subdermal drug implant candidates using its proprietary NanoPortal™ technology. News commonly centers on financial results, business updates, manufacturing and clinical-development spending, and progress for semaglutide-based implant candidates such as NPM-139 for chronic weight management and NPM-133 for type 2 diabetes.
The company’s updates also cover Cortigent, its wholly owned subsidiary developing brain implant devices based on precision neurostimulation technology. Cortigent disclosures include the Orion® Visual Cortical Prosthesis System, a cortical stimulation system under development to provide visual perception for blind persons, as well as equity financings, registered direct offerings, private placements, shareholder matters and governance updates.
Vivani Medical (Nasdaq: VANI) reported Q1 2026 results and a pipeline update. The SLIM-1™ Phase 1 trial of semaglutide implant NPM-139 is expected to start mid-2026, with top-line data by year-end. Vivani held about $28 million in cash and commitments, projected to fund operations through the first half of 2027, and reported a Q1 2026 net loss of $6.8 million. The company is also evaluating paths to separate neuromodulation subsidiary Cortigent into an independent public company.
Vivani Medical (Nasdaq: VANI) reported Q4 and full-year 2025 results and a business update highlighting clinical and preclinical progress for a semaglutide implant (NPM-139) and financing that extends runway into mid-2027.
The company reported sustained preclinical semaglutide exposure with >20% sham-adjusted weight loss for one year, plans to start a Phase 1 study mid-2026 with data possible by end-2026, and raised $41.5M in recent financings.
Vivani (NASDAQ: VANI) announced that subsidiary Cortigent presented 6-year Early Feasibility Study results for the Orion visual cortical prosthesis at NANS 2026. Six subjects implanted 2018–2019 completed the study in March 2025, showing improved visual test performance with devices functional and <4% electrode loss.
One early seizure occurred; stimulation was adjusted and no further serious adverse events were reported. Cortigent plans to discuss a larger pivotal trial with the FDA in 2026.
Vivani Medical (Nasdaq: VANI) closed a registered direct offering and a concurrent private placement on January 27, 2026, selling a combined 3,040,551 shares at $1.48 per share for gross proceeds of approximately $4.5 million before fees and expenses. The private placement included 1,351,351 shares purchased by Chairman Gregg Williams. Proceeds are intended to fund ongoing research and clinical development of NanoPortal implants, plus working capital and general corporate purposes. ThinkEquity acted as sole placement agent for the registered offering.
Vivani Medical (Nasdaq: VANI) priced a best-efforts registered direct offering of 1,689,200 shares and a concurrent private placement of 1,351,351 shares at $1.48 per share.
Gross proceeds are expected to be approximately $4.5 million before fees and expenses. The private placement purchaser is Gregg Williams, chairman of the board. The offerings are expected to close on or about January 27, 2026, and net proceeds will fund research and clinical development, working capital and general corporate purposes.
Vivani (NASDAQ: VANI) subsidiary Cortigent will present an award-winning poster on Jan 23, 2026 at the North American Neuromodulation Society annual meeting describing the investigational Orion Visual Cortical Prosthesis System. The company says Orion completed a six-year Early Feasibility Study and is designed to elicit visual phosphenes via a 60-electrode cortical surface array paired to an implantable pulse generator with 60 outputs in a package about the size of three stacked dimes and a wireless wearable for real-time processing.
The poster highlights miniature, high-channel-count stimulation and real-time parameter control; it notes the electrode design derives from retinal implant experience with Argus II, which remained functional in retinal tissue for >17 years and was the only FDA-approved artificial vision device.
Vivani Medical (Nasdaq: VANI) reported third quarter 2025 results and a business update on Nov 13, 2025. The company completed LIBERATE-1, its first human test of the NanoPortal implant, and reported preclinical NPM-139 data showing 20% weight loss sustained for over 7 months. Vivani plans to initiate a Phase 1 semaglutide implant study in the first half of 2026 and is preparing a Phase 2 dose-ranging study pending Phase 1 results and regulatory feedback.
Financings in 3Q and October generated approximately $25.7 million in cash and commitments to support NPM-139 development and, as of Sept 30, 2025, Vivani held $4.0 million in cash. The company expects to complete the spin-off of Cortigent after the SEC resumes operations.
Vivani Medical (Nasdaq: VANI) closed a registered direct offering of 6,000,000 common shares and a concurrent private placement of 3,703,703 common shares on Oct 28, 2025 at $1.62 per share, generating approximately $15.7 million gross before fees and expenses.
The private placement purchaser was Gregg Williams, Chairman of Vivani’s board. The offerings were priced at-the-market under Nasdaq rules and used a Form S-3 shelf registration declared effective May 3, 2024. Net proceeds are intended to fund research and clinical development, plus working capital and general corporate purposes.
Vivani Medical (Nasdaq: VANI) priced a best-efforts registered direct offering of 6,000,000 common shares and a concurrent private placement of 3,703,703 common shares to Gregg Williams at $1.62 per share.
The combined gross proceeds are expected to be approximately $15.7 million before fees and expenses; closing is expected on or about October 28, 2025, subject to customary conditions. ThinkEquity is sole placement agent. Proceeds are intended to fund ongoing research and clinical development, plus working capital and general corporate purposes.
Vivani Medical (NASDAQ: VANI) announced that CEO Adam Mendelsohn, Ph.D. will present at the ThinkEquity Conference on October 30, 2025 in New York.
Presentation is scheduled for 1:30 p.m. Eastern Time at the Lotus Suite East, Mandarin Oriental Hotel, 80 Columbus Circle. A webcast will be available on the company Investors page and via the provided Summitcast link.